1. Bulman, D.E., Murphy, E.G., Zubrzycka-Gaarn, E.E., Worton, R.G. and Ray, P.N. 1990. Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino-and carboxyterminal antisera specific for dystrophin.
2. Chamberlain, J.S., Gibbs, R., Ranier, J.E., Nguyen, P.N. and Caskey, C.T. 1988. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucl. Acids Res. 1: 1 1141.
3. Hoffman, E.P.,Fischbeck, K.H.,Brown, R.H.,Johnson, M.,Medori, R. et al. 1988. Dystrophin quality and quantity determines the clinical severity of Duchenne/Becker Muscular Dystrophies. New Eng. J. Med., 318: 1363.
4. Karpati, G., Pouliot, Y., Zubrzycka-Gaarn, E.E., Carpenter, S., Ray, P.N., Worton, R.G. and Holland, P. 1989. Rapid communication, dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. Am. J. Path., 135: 27.
5. Koenig, M., Hoffman, E.P., Bertelson, C.J., Monaco, A.P., Feener, C. and Kunkel, L.M. 1987. Complete cloning of the Duchenne muscular dystrophy ( DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 50: 509.